Kornimate/medical-research-clean huggingface dataset:
effect dietary fibre supplementation on gut microbiota composition

Conditions: Diet, Healthy; Systemic Inflammatory Response

Summary: the study involves taking pectin fibre at increasing doses ranging from 5g, 10g and 15g for a total period of 6 weeks with the increase every 2 weeks. study subjects will be healthy volunteers recruited from the university and local population and will be asked to attend the laboratory on 4 occasions; at the start of the intervention and every 2 weeks, at the end of each dosing period. at each study visit (\~3hrs), participants will be asked to provide a stool and blood sample and will have blood pressure measured. in the week before each study visit, participants will record their food intake.

the study aims to assess the optimal dosage of pectin required to see beneficial effects on inflammation and gut microbiome composition. 15 healthy, non-obese volunteers will be recruited following a successful medical screening. between recruitment and first study visit, and at the end of each dosing period (before each study visit), participants will be asked to complete a dietary record (4 days), to collect a stool sample on the day before the study visit and to fast from midnight the night before this visit. at both study visits, participants will have weight, hip/waist circumference and blood pressure measured. they will be asked to complete some questionnaires. after completion of the first study day, participants will be provided with the required dosage of pectin for the 2-week dosing period. they will be given the required doses of pectin portioned in individual sachets, with instructions to add the contents of one sachet a day to juice, smoothies or water and to consume immediately. study visits will be scheduled at the end of every 2-weeks.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study * participant eligibility includes those aged \>18 years who have a body mass index (bmi) between 18.5 and 39.9 kg/m2 exclusion criteria: * have psychosocial or gastrointestinal (e.g. malabsorptive conditions such as ibs/ibd, coeliac) * are taking the following medications: immunosuppressants, anti-histamines, amiodarone and/or perhexiline * are currently following or anticipated to commence a specialised commercially available weight loss diet and/or program/ taking prebiotic supplements * pregnant or breast feeding * history or current psychiatric illness * history or current neurological condition (e.g. epilepsy) * having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Keywords: dietary intervention gut microbiome dose- response systemic inflammation
total hip arthroplasty instability and lumbo-pelvic kinematics: eos imaging assessment of variation in spinal and pelvic parameters from standing to sitting

Conditions: Hip Fractures

Summary: the authors hypothesize that a pelvic kinematic disorder, demonstrated by a significant decrease in sacral slope, is associated with the risk of instability of total hip prosthesis, the sacral slope being measured by an eos imaging system during the transition to sitting in unstable patients versus patients with no history of instability.


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient must be at least 18 years old and less than 85 years old * patient has a conventional first intention total hip arthroplasty (not dual mobility) by posterior approach * "case" patients have at least one previous episode of prosthetic dislocation repaired with surgery * "control" patients have no previous episode of prosthetic dislocation with more than 2 year since initial intervention exclusion criteria: * the subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * patient is pregnant, parturient or breastfeeding * patient with lumbar instrumentation * patient with severe dementia (mini mental state examination \< 10) * patient with american society of anesthesiologists score ≥ 4 * patient experience multiple falls * patient requiring early revision surgery (\<15 days postoperatively * patient with obvious implant positioning error on an x-ray of the pelvis. * patient with dislocation of traumatic origin (significant kinetic trauma)
support for cancer patients awaiting news

Conditions: Lung Cancer

Summary: this is a behavioral trial study to pilot test a stress management intervention for people with cancer who are undergoing routine cancer scans. the study will involve two pilot testing phases. initial feasibility will be determined in an open trial phase, to inform any needed revisions to the intervention and/or protocol prior to a pilot randomized controlled trial phase. the open trial phase is an unblinded, single-site, single-arm open trial (n=10). the pilot randomized clinical trial (rct) phase is an unblinded, single-site, feasibility pilot randomized controlled trial (n=50).

advanced cancer patients repeatedly undergo routine scans that inform their disease status and treatment. while awaiting the results, anxiety and uncertainty are elevated, which can negatively impact quality of life. evidence-based stress management strategies have the potential to be useful during this unique time period, but require tailoring for this population and context. the goal of this study is to pilot test an adapted stress management program to help patients manage their anxiety while awaiting scan results. the program is a behavioral intervention that includes psychoeducation and stress management activities, delivered via a web platform to promote dissemination. in the open trial phase, the program will be field tested in a single-arm trial, using feedback to refine materials and procedures as needed before formal piloting. in the pilot rct phase, a small rct will be conducted to test the intervention's feasibility and acceptability and to examine preliminary effects on anxiety and cancer-related intrusive thoughts.

Eligibility criteria:
inclusion criteria: 1. adult (ages 18 and older) 2. comfortable speaking, reading, and writing english without an interpreter 3. established diagnosis of stage iii-iv lung cancer (or extensive stage small cell lung cancer) 4. ecog (eastern cooperative oncology group) performance status of 0 to 2 5. receiving ongoing care from collaborating clinics with regular scans 6. receiving systemic treatment for lung cancer 7. endorse appointment- or scan-related stress on 4-item screen (using a modified distress thermometer item, a fear of progression scale item, an impact of events scale item, and an item from our prior study) 8. willingness to use the study website exclusion criteria: 1. moderate-to-severe cognitive impairment (per dementia diagnosis or cognitive screen) 2. requires an interpreter for medical visits 3. severe psychiatric illness (psychiatric hospitalization in the past year, or substance use disorder, bipolar disorder, or psychosis diagnosis) 4. currently enrolled in hospice 5. unable to complete study activities per oncology provider's judgment (e.g., due to fatigue)

Keywords: stress management cancer related anxiety scan related anxiety advanced lung cancer
does the "tookie vest" reduce line fall out rate in children?

Conditions: Childhood Cancer

Summary: the objective of the trial is to assess whether the tookie vest is an effective intervention in reducing line fall out. all oncology patients with a tunneled central line will be approached to participate in this study. following informed consent they will be issued with a tookie vest.

all oncology patients with a tunneled central line will be approached to participate in this study. following informed consent they will be issued with a tookie vest. lines will be studied for the duration they are in situ. this will vary depending on the underlying diagnosis and treatment regime. one hundred central line insertions for oncology patients will be prospectively identified and be given the "tookie vest" to wear. data will be collated for each group regarding age, gender, diagnosis, type of central access inserted, duration of line, reason for removal, in cases of infection the infected organism will be documented, date of each fall out.

Eligibility criteria:
inclusion criteria: * any child receiving treatment for malignancy at royal manchester children's hospital * patients with a tunnelled central line inserted for treatment of their malignancy exclusion criteria: • any child having a portacath inserted as their mode of central access
risk of qt-prolongation and torsade de pointes in patients treated with acute medication in a university hospital

Conditions: Delirium; QT-prolongation

Summary: a prospective, observational study in a university hospital (uz leuven). patients are included when they are treated with a potentional qt-prolonging drug: haloperidol for delirium, antibiotics (moxifloxacin, levofloxacin, azithromycin, clarithromycin, erythromycin, co-trimoxazole), antimycotics (ketoconazole, itraconazole, fluconazole, voriconazole), methadone, tacrolimus and oral oncolytics. an ecg is taken before the administration of the drug and 3-5 days after starting the drug to investigate the change in duration of the qtc-interval. risk factors for developing qt-prolongation will be documented. together with ecg2, an additional blood sample will be collected to measure the blood concentration of the drug.


Eligibility criteria:
inclusion criteria: * treatment with a potentional qt-prolonging drug of our list * inpatient of uz leuven, admitted on one of the participating wards exclusion criteria: * \< 18 years old * dnr-code 3 * not possible to take an ecg before the start of haloperidol

Keywords: qt-prolongation torsade de pointes qt-prolonging drugs
efficacy of artesunate-amodiaquine and artemether-lumefantrine for treatment of plasmodium falciparum malaria in liberia

Conditions: Plasmodium Falciparum; Malaria; Uncomplicated Malaria

Summary: to assess the efficacy of both first-line antimalarial medications used for the treatment of uncomplicated plasmodium falciparum malaria infections in two geographic regions in liberia.

title: efficacy of artesunate+amodiaquine (asaq) and artemether+lumefantrine (al) for the treatment of uncomplicated plasmodium falciparum malaria in liberia objective: to assess the efficacy of both first-line asaq and al for the treatment of uncomplicated p. falciparum malaria infections study sites: sacleapea comprehensive health center, saclepea-mah district in nimba county; and sinje health center, garwula district, sinje, in grand cape mount county study period: august 2022 to august 2023 study design: prospective study of two cohorts with simultaneous enrolment of each therapy patient population: patients aged 6 to 59 months with confirmed uncomplicated p. falciparum infection sample size: total number of patients to be enrolled is 352 patients. this consists of 88 patients per arm per site. there are two arms in each of the two sites. treatment(s) and follow-up: patients enrolled in the asaq arm will receive the treatment once daily dose for three days. patients enrolled in the al arm will receive treatment twice daily dose for three days. clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy. primary endpoints: the proportion of patients with early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response as indicators of efficacy. recrudescence will be distinguished from re-infection by polymerase chain reaction (pcr) analysis. secondary endpoints: the frequency and nature of adverse events will be recorded. exploratory endpoints: any polymorphisms of molecular markers for antimalarial drug resistance and prevalence of hrp2 deletions.

Eligibility criteria:
inclusion criteria 1. age between 6 to 59 months (5 years) 2. weight ≥ 5 kg 3. monoinfection with p. falciparum with a parasite density of 2,000 to 200,000 asexual forms per microliter of blood 4. axillary temperature ≥37.5˚c or history of fever in the last 24 hours 5. hemoglobin ≥ 8.0g/dl 6. easy access to the health facility and ability to return to the health facility over the course of the four weeks of follow-up 7. informed consent of parent or guardian exclusion criteria on day 0 1. any danger signs or signs of severe malaria (see appendix i) 2. pneumonia or bronchopneumonia 3. severe malnutrition (z-score \< 3) 4. history of taking antimalarials (or antibiotics with antimalarial activity such as cotrimoxazole, tetracycline or doxycycline) in the last 14 days 5. mixed malaria infection 6. history of hypersensitivity or allergy to the medication

Keywords: plasmodium falciparum anti-malarial therapeutic efficacy study (tes) artemisinin-based combination therapies (act)
hepatic impaired subjects compared to healthy subjects receiving multi-dose bms-650032

Conditions: Hepatic Insufficiency

Summary: the purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of bms-650032.


Eligibility criteria:
inclusion criteria: * male and female subjects aged 18 to 70, with hepatic impairment conforming to child-pugh class a,b or c * each matched control subjects determined to be healthy exclusion criteria: * history of esophageal and gastric bleeding within the past 6 months * primarily cholestatic liver disease * active alcoholic hepatitis * stable encephalopathy of ≥stage 2 * presence of severe ascites or edema * presence of hepatopulmonary or hepatorenal syndrome * positive for hiv * positive for hcv, unless hcv rna is undetectable
a phase ii study of gemcitabine and capecitabine for treatment resistant, metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the present study aims to investigate the efficacy and safety of the combination of capecitabine and gemcitabine in heavily pre-treated, treatment resistant metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: * histologically verified colorectal adenocarcinomas * age \> 18 years * metastatic colorectal cancer refractory to 5-fu, oxaliplatin, irinotecan and relevant biological agents. * measurable disease according to recist 1.1 * ecog performance status 0, 1 or 2 * adequate renal, hepatic and haematological function * consent to blood samples and available paraffin embedded tumour material for translational research studies * fertile males and females (\<2 years after last period for women) must use effective birth control. * signed informed consent exclusion criteria: * clinically significant concurrent disease. * other malignant diseases within 5 years of inclusion in the study, except squamous cell carcinoma of the skin and cervical carcinoma-in-situ. * other experimental therapy within 30 days of treatment initiation. * patients who are breast feeding, childbearing or of childbearing potential without using dual effective contraception. * clinical or radiological evidence of cns metastasis. * planned radiation therapy against target-lesions. * known allergy to 5fu/capecitabine or gemcitabine.

Keywords: colorectal cancer metastatic treatment resistant
efficacy and mechanism of rtms in children with asd: an open-label clinical trial(ⅱ)

Conditions: Autism Spectrum Disorder

Summary: this study is a open-label clinical trial involving over 30 asd children aged ≥4 years old. during the study, subjects received repeated transcranial magnetic stimulation (rtms) intervention on the left primary motor cortex (m1) 10 times per day for 5 consecutive days and complete clinical assessments from pre-intervention to post-intervention. this study hopes to explore whether accelerated continuous theta-burst stimulation (a-ctbs) over left primary motor cortex (m1) can improve clinical symptoms of children with asd in china.

this study is a single-arm open-label clinical trial, designed to enroll at least 30 children with asd aged over 4 years old. during the trial, participants will receive accelerated continuous theta-burst stimulation (a-ctbs)on the left primary motor cortex (m1) for 5 consecutive days and complete clinical assessments within 2 weeks before the ctbs intervention (pre-ctbs), repeated within 3 days after the completion of the ctbs course (post-ctbs) and 1 month following the last ctbs session (one month follow-up), respectively. the purpose of this current study is to explore whether rtms can improve the clinical symptoms of children with autism spectrum disorder in china, and to investigate the neurophysiological mechanism of rtms for asd children.

Eligibility criteria:
inclusion criteria: * children aged ≥4 years. * meeting the diagnostic criteria of the diagnostic and statistical manual of mental disorders, edition 5 (dsm-5) . * confirmed by the ados and/or adi-r diagnostic tool. * informed consent. exclusion criteria: * patients with metal implants . * patients with neurological diseases such as epilepsy . * patients requiring surgical treatment due to structural abnormalities indicated by brain mri . * genetic or chromosomal abnormalities . * suffering from mental disorders (such as mood disorders, etc.) * suffering from serious heart disease . * hearing-impaired . * intracranial hypertension . * participating in other clinical trials. * participants who received other interventions within 4 weeks prior to enrollment.

Keywords: repetitive transcranial magnetic stimulation（rtms） continuous theta burst stimulation （ctbs）
cryptosporidium species in sohag governorate

Conditions: Cryptosporidiosis

Summary: cryptosporidium species are increasingly recognized as important enteric pathogens that infect a broad range of hosts including human, domestic and wild animals worldwide, causing asymptomatic or mild-to-severe gastrointestinal disease in their host species. there are 38 species of cryptosporidium that have been described, going from amphibian parasites to mammals ones, with over 40 genotypes infecting mammals, although cryptosporidium parvum and cryptosporidium hominis are the two species predominantly reported in human infections. in cairo and sharkyia governorates in egypt, cryptosporidium is a common intestinal parasite among children, especially in diarrheic, preschool-aged children, with a predominance of c. hominis indicates anthroponotic rather than zoonotic transmission. also in the sohag governorate, cryptosporidium infection is a common intestinal parasite, as in the last five years its prevalence about 35% but there is no study clarify predominant genotype of cryptosporidium in sohag.


Eligibility criteria:
inclusion criteria: 1. age: any age 2. sex: male -female 3. residence: rural-urban 4. animal contact. 5. immune status: immunocompetent - immunocompromised 6. clinical manifestations: diarrhea -abdominal pain- fever- vomiting. exclusion criteria: * patients taking treatment for cryptosporidiosis
comparison of two radial artery segments related to "old-fashioned" radial and new snuff box vessel approach by us

Conditions: Heart Diseases

Summary: the purpose of this study is to determine if there is a difference in the size and the depth of the radial artery at the access points for established radial and new distal radial approach for the arteries of both arms

radial approach for coronary and peripheral procedures is now well established due to both patient and operator preference and carries a lower risk of bleeding and mortality. the most lasting consequence of transradial procedures remains radial artery occlusion, which is mainly influenced by the artery diameter and the size of the sheath. as a new, more distal approach looms on the horizon, it is plausible to determine factors that could impact its feasibility. since the success rate for artery cannulation depends to a great extent on the size and the depth of the artery, the current study examines both parameters, as well as whether they are influenced by variables such as sex, body mass index, handedness, or comorbidities i.e. diabetes mellitus and hypertension.

Eligibility criteria:
inclusion criteria: * patients \>18 years old admitted to the cardiology department exclusion criteria: * previous transradial procedures * arm av fistula for dialysis access * history of upper limb peripheral arterial disease * hemiparesis * hemodynamic instability
clinical trial to assess efficacy and safety of the human anti-cd38 antibody felzartamab (mor202) in iga nephropathy

Conditions: Immunoglobulin A (IgA) Nephropathy

Summary: randomized, placebo-controlled, multi-center, double-blind, proof of concept phase iia trial and dose evaluation trial of felzartamab in igan

study sponsor, originally hi-bio, inc., is now hi-bio, a biogen company.

Eligibility criteria:
key inclusion criteria: * patients ≥ 18 to ≤ 80 years (at date of signing the informed consent form \[icf\]), but at least of legal age in the given country * biopsy confirmed diagnosis of igan within the past 8 years prior to signature of the icf * proteinuria at screening visit ≥ 1.0 g/d. * treatment with an angiotensin-converting enzyme inhibitor (acei) and/or angiotensin receptor blocker (arb) at maximum doses or maximally tolerated doses for ≥ 3 months prior to date of informed consent and adequate blood pressure (bp) control. * a female of childbearing potential (fcbp), is only eligible to participate if she is not pregnant, not breast feeding, and agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of imp key exclusion criteria: * hemoglobin \< 90 g/l * thrombocytopenia: platelets \< 100.0 x 10\^9/l. * neutropenia: neutrophils \< 1.5 x 10\^9/l. * leukopenia: leukocytes \< 3.0 x 10\^9/l * diabetes mellitus type 1 * aspartate aminotransferase or alanine aminotransferase \>1.5 x uln, alkaline phosphatase \>3.0 x uln

Keywords: kidney disease urologic disease glomerular disease berger disease glomerulonephritis, iga
clinical trail to evaluate the efficacy and safety of adhesion barrier mediclore versus no treatment in patients with total thyroidectomy

Conditions: Patients With Thyroidecomy (Scheduled)

Summary: a randomized, single-blind, multi-center, phase iii clinical trial to evaluate the efficacy and safety of adhesion barrier mediclore versus no treatment in patients with total thyroidectomy


Eligibility criteria:
inclusion criteria: * written informed consent * male or female at least 20 years of age * patients without clinically significant lab * patients scheduled for thyroidectomy exclusion criteria: * another clinical trials within 1 month * history of previous surgery on same position * anticoagulant, general steroids within a week from surgery * immunosuppression or autoimmune disease * general or local infection * serious diseases (heart failure, renal failure, liver failure, uncontrolled hypertentsion, diabetes mellitus, coagulation deficiencies) * incompatible medications * history of drug or alcohol abuse, mental disorder * pregnant or lactating women and fertile women who is not using proper contraceptive method * history of esophagus diseases * keloid symptoms